Ann: Central Nervous System Drug Program Added to PYC Pipeline, page-28

You are right @hottod Autism Spectrum Disorder (ASD) could be caused by a monogenic or heterogenic neurodevelopmental disorder.

ASD is a common condition, and the number of children diagnosed with ASD has been increasing rapidly in the past few decades. In 2021, the prevalence of the disorder in the United States is estimated at 1 in 44 children.

In most individuals with ASD caused by rare gene mutations, the mutations occur in only a single gene. SHANK3 in particular is the target for PYC's 3rd pipeline drug to treat Phelan-McDermid Syndrome.

Genes associated with ASD are:

• ADNP

ANK2ARID1BASH1LCHD2CHD8CTNND2DYRK1AGRIN2BKCNQ3MECP2
POGZPTENRELNSHANK3SYNGAP1UBE3A

• ASXL3

CACNA1HCNTN4CNTNAP2DSCAMEIF4E**RB3KATNAL2KCNQ5KDM5A
KDM5BMYT1LNLGN1NLGN3NRXN1PTCHD1
RPL10SCN2ASHANK2SYN1SYN2TBR1TMLHE

PYC's stealthy patent filing DID NOT mention which gene it is applying to. One simplistic assumption is those 4 patents would refer to 4 different genes. Now it is not hard to image that PYC is working on 3 other monogenic disorders yet to be announced! Leveraging on PYC's efficient and low toxicity drug delivery platform and Professor Sue Fletcher's proven ability to engineer RNA cargos, the team would certainly deliver dugs for the druggable diseases in the next 2-3 years.

Reference:
https://medlineplus.gov/genetics/condition/autism-spectrum-disorder/#inheritance